KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Twist Bioscience (TWST) Research & Development (2017 - 2026)

Twist Bioscience has reported Research & Development over the past 10 years, most recently at $19.7 million for Q1 2026.

  • Quarterly Research & Development fell 17.65% to $19.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $71.9 million through Mar 2026, down 19.07% year-over-year, with the annual reading at $80.3 million for FY2025, 11.63% down from the prior year.
  • Research & Development was $19.7 million for Q1 2026 at Twist Bioscience, up from $17.1 million in the prior quarter.
  • Over five years, Research & Development peaked at $36.8 million in Q2 2022 and troughed at $17.0 million in Q3 2025.
  • The 5-year median for Research & Development is $23.7 million (2023), against an average of $24.3 million.
  • Year-over-year, Research & Development soared 97.78% in 2022 and then crashed 33.42% in 2023.
  • A 5-year view of Research & Development shows it stood at $31.2 million in 2022, then dropped by 26.06% to $23.1 million in 2023, then dropped by 7.76% to $21.3 million in 2024, then fell by 19.6% to $17.1 million in 2025, then grew by 14.97% to $19.7 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Research & Development are $19.7 million (Q1 2026), $17.1 million (Q4 2025), and $17.0 million (Q3 2025).